Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP‐1

Kozma, Gergely Tibor; Falus, András; Bojszkó, Ágnes; Krikovszky, Dóra; Szabó, T; Nagy, Adrienne; Szalai, Csaba

doi:10.1034/j.1398-9995.2002.1s3361.x

Cited by 41 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7][8][9][10][11][12] Therefore, RANTES could be considered a gene generally predisposing to autoimmune disease. To test this hypothesis, we investigated RANTES SNPs rs2306630, rs2280788 and rs2107538 in a group of 310 CD patients.…”

Section: Discussionmentioning

confidence: 99%

“…This gene has not yet been investigated in the context of T1D, although it has been shown to be associated with other autoimmune diseases, such as atopic dermatitis, asthma, sarcoidosis, rheumatoid arthritis and multiple sclerosis. [5][6][7][8][9][10][11][12] RANTES belongs to the family of CC chemokines, which are involved in immunoregulatory and inflammatory processes owing to their ability to recruit, activate and co-stimulate T cells and monocytes. 13,14 In addition to the trafficking effect, RANTES, like other CC chemokines, plays an important role in co-stimulation of T-cell proliferation 15,16 and activation of the T cells localized in the inflammatory lesion.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes

et al. 2006

View full text Add to dashboard Cite

RANTES (regulated on activation, normal T-cell expressed and secreted) is a T-helper type 1 (Th1) chemokine that promotes T-cell activation and proliferation. RANTES is genetically associated with asthma, sarcoidosis and multiple sclerosis. The concentration of RANTES is increased at inflammation sites in different autoimmune diseases. Type 1 diabetes (T1D) is a Th1-mediated disease with complex genetic predisposition. We tested RANTES as a candidate gene for association with T1D using three single-nucleotide polymorphism (SNP) variants (rs4251719, rs2306630 and rs2107538) to capture haplotype information. The minor alleles of all SNPs were transmitted less frequently to T1D offspring (transmission rates 37.3% (P ¼ 0.002), 38.7% (P ¼ 0.007) and 41.0% (P ¼ 0.01)) and were less frequently present in patients compared to controls (P ¼ 0.009, 0.03 and 0.04, respectively). A similar protective effect was observed for the haplotype carrying three minor alleles (transmission disequilibrium test (TDT): P ¼ 0.003; odds ratio (OR) ¼ 0.55; confidence interval (CI): 0.37-0.83; case/control: P ¼ 0.03; OR ¼ 0.74; CI: 0.55-0.98). Both patients and controls carrying the protective haplotype express significantly lower serum levels of RANTES compared to non-carriers. Subsequently, we tested a cohort of 310 celiac disease patients, but failed to detect association. RANTES SNPs are significantly associated with RANTES serum concentration and development of T1D. The rs4251719*A-rs2306630*A-rs2107538*A haplotype associated with low RANTES production confers protection from T1D. Our data imply that RANTES is associated with T1D both genetically and functionally, and contributes to diabetesprone Th1 cytokine profile.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes

et al. 2006

View full text Add to dashboard Cite

show abstract

“…In addition, the GG genotype correlated with asthma severity and the G allele was associated with increased blood eosinophil levels 20 . However, there was no association between MCP-1-2518 and atopic eczema/dermatitis syndrome or allergy in a cohort of Hungarian children 21 . In case of sarcoidosis, MCP-1-2518 does not play a substantial role in the disease susceptibility, but might be related to the recruitment of monocytes/macrophages to the alveolar spaces in Japanese patients with sarcoidosis 22 .…”

Section: Lung Diseasesmentioning

confidence: 99%

Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases

Navratilova¹

2006

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

“…8 The activities of CCL5 are mediated through its binding to CCR1, CCR3 and CCR5. 9 Genetic evidence exists that links CCL5 with numerous human diseases, such as coronary artery disease, 10 multiple sclerosis, 11 rheumatoid arthritis, 12,13 asthma and atopy, [14][15][16][17] atopic eczema/dermatitis syndrome, atopic dermatitis, 18 hepatitis C virus infection, 19,20 heart graft rejection 21 and systemic lupus erythematosus. 22,23 …”

Section: Ccl5 Produced By Cd8mentioning

confidence: 99%

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer

Zhang

Kim

et al. 2013

Cell Mol Immunol

View full text Add to dashboard Cite

Breast cancer (BC) is a leading cause of mortality among women in the world. To date, a number of molecules have been established as disease status indicators and therapeutic targets. The best known among them are estrogen receptor-a (ER-a), progesterone receptor (PR) and HER-2/neu. About 15%-20% BC patients do not respond effectively to therapies targeting these classes of tumor-promoting factors. Thus, additional targets are strongly and urgently sought after in therapy for human BCs negative for ER, PR and HER-2, the so-called triple-negative BC (TNBC). Recent clinical work has revealed that CC chemokine ligand 5 (CCL5) is strongly associated with the progression of BC, particularly TNBC. How CCL5 contributes to the development of TNBC is not well understood. Experimental animal studies have begun to address the mechanistic issue. In this article, we will review the clinical and laboratory work in this area that has led to our own hypothesis that targeting CCL5 in TNBCs will have favorable therapeutic outcomes with minimal adverse impact on the general physiology.

show abstract

Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP‐1

Abstract: In this cohort of Hungarian children there was no association between - 28G, and - 403A alleles in the RANTES promoter, - 2518G polymorphism in the distal regulatory region of the MCP-1 and AEDS, or allergy.

Cited by 41 publications

References 22 publications

Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes

Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes

Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer

Contact Info

Product

Resources

About